<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115682</url>
  </required_header>
  <id_info>
    <org_study_id>HIT Metabolome</org_study_id>
    <nct_id>NCT05115682</nct_id>
  </id_info>
  <brief_title>Circadian Rhythm and Metabolic Effects of Exercise</brief_title>
  <acronym>HITMet</acronym>
  <official_title>Time of Day Specific Glycaemic and Metabolic Response to High-Intensity Interval Training</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physical exercise is efficacious in controlling blood glucose levels in individuals with Type&#xD;
      2 diabetes. An individual's exercise capacity and ability to utilize glucose as an energy&#xD;
      source oscillates throughout the day. Hence, the beneficial effects of exercise on blood&#xD;
      glucose levels may depend on the time of day when the exercise bout is performed. However,&#xD;
      the time of day in which the most beneficial adaptations to exercise can be achieved remains&#xD;
      unknown. This project aims to answer the following questions: Does time of day impact the&#xD;
      beneficial effects of exercise on blood glucose? If so, when can the most beneficial effects&#xD;
      of exercise be achieved? Which metabolic mechanisms links time of day, exercise and blood&#xD;
      glucose control? To address these questions, individuals with or without Type 2 diabetes will&#xD;
      perform an exercise session at two different times (09:00 and 16:00), and continuous glucose&#xD;
      monitoring will be used to assess the effects of exercise on blood glucose. We will determine&#xD;
      the specific metabolic processes which promote the most beneficial blood glucose response. To&#xD;
      achieve this, we will measure which metabolic substrates (carbohydrates, lipids and proteins)&#xD;
      are used and which metabolites produced in blood, skeletal muscle and adipose tissue in&#xD;
      response to exercise at different times of the day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exercise has well-established metabolic benefits and is a preferred intervention for Type 2&#xD;
      diabetes prevention and management. Metabolic determinants of exercise such as skeletal&#xD;
      muscle and whole-body substrate oxidation capacity, glucose tolerance and insulin sensitivity&#xD;
      and adipose tissue fatty acid release all show circadian oscillations. These rhythms may&#xD;
      promote substantially different responses depending on the time of day when exercise is&#xD;
      performed.&#xD;
&#xD;
      This is an exploratory study aiming to determine whether exercise at specific times of day&#xD;
      can amplify the beneficial effects on glycemia and metabolism in twi groups of individuals:&#xD;
      those with normal glucose tolerance (NGT) or Type 2 diabetes (n=40 per group). The primary&#xD;
      objective is to determine the glycemic response to an exercise bout at two distinct times of&#xD;
      day, measured by continuous glucose monitoring, in men and women with NGT or Type 2 diabetes.&#xD;
      The secondary aim is to identify specific metabolites which facilitate the strongest glycemic&#xD;
      response to exercise by examining the whole-body and peripheral tissue metabolomic response&#xD;
      to an exercise bout.&#xD;
&#xD;
      The primary goal of the study is to examine the glycemic and metabolic response to exercise&#xD;
      within-group for participants with NGT or Type 2 diabetes. Further comparisons will be made&#xD;
      between groups with NGT or Type 2 diabetes, across sexes, and by individual chronotype&#xD;
      (determined by a standardized questionnaire) to examine the variation in the exercise&#xD;
      response across these parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study will include a group of individuals with type 2 diabetes and a group of individuals with normal glucose tolerance. Each group of participants will complete either a morning (09:00) or an afternoon (16:00) exercise bout. After a one-week washout period, the participants will complete an additional exercise bout at the opposing time.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise-induced Changes in 24 Hour Interstitial Glucose Concentration</measure>
    <time_frame>3 days (1 day before to 1 day after exercise)</time_frame>
    <description>Glucose excursions will be charted using continuous interstitial glucose monitors. The day immediately before exercise will be used as baseline, the day of exercise to assess the acute response, and the day after exercise to assess lasting effects on glycemia. Exercise effects on glucose concentration will be primarily assessed by comparing 24-hour curves between conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Exercise-induced Changes in Interstitial Glucose Concentration</measure>
    <time_frame>2 hours (0 minutes before to 120 minutes after exercise)</time_frame>
    <description>Glucose will be charted using continuous glucose monitors. Acute response to exercise, during the exercise bout and during an additional 120 minutes will be compared between conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Glucose Concentration Response to a Meal</measure>
    <time_frame>2 days (1 day before and day of exercise)</time_frame>
    <description>Glucose will be charted using continuous glucose monitors. Three standardized meals per day will be provided on each occasion for the day before, day of and day after exercise. The 120 minute glucose response to the standardized meal succeeding an exercise bout will be compared to the same meal on a baseline (no exercise) day and between the two exercise times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Glucose Concentration Variability</measure>
    <time_frame>3 days (1 day before to 1 day after exercise)</time_frame>
    <description>Glucose will be charted using continuous glucose monitors. The day immediately before exercise will be used as baseline, the day of exercise to assess the acute response, and the day after exercise to assess lasting effects on glucose concentration variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent in Interstitial Glucose Concentration Range</measure>
    <time_frame>3 days (1 day before to 1 day after exercise)</time_frame>
    <description>Glucose will be charted using continuous glucose monitors. The day immediately before exercise will be used as baseline, the day of exercise to assess the acute response, and the day after exercise to assess lasting effects on glycemic variability. Daily time spent in low (&lt;3.9mmol/L), high (&gt;10mmol/L) and within target glycemic range (3.9-10mmol/L) will be calculated on each occasion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Interestitial Glucose Concentration</measure>
    <time_frame>2 days (day of, and 1 day after exercise)</time_frame>
    <description>Glucose will be charted using continuous glucose monitors. The day immediately before exercise will be used as baseline, the day of exercise to assess the acute response, and the day after exercise to assess lasting effects on glycemic variability. Nocturnal glycemia (00:00-06:00) for each day will be compared on each exercise occasion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Response to Exercise</measure>
    <time_frame>1 hour (5 minutes before, 5 minutes after and 60 minutes after exercise)</time_frame>
    <description>Changes in blood, skeletal muscle and subcutaneous adipose tissue metabolite levels will be assessed by broad-spectrum, untargeted metabolomics. Samples will be collected immediately before (-5 minutes) and after (+5 minutes) each exercise bout. An additional blood sample will be collected one hour after exercise completion (+60 minutes).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Circadian Rhythm</condition>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>Morning First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete a single bout of exercise at 09:00, and after at least a one-week washout perform another exercise bout at 16:00.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afternoon First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete a single bout of exercise at 16:00, and after at least a one-week washout perform another exercise bout at 09:00.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High-intensity Intermittent Exercise</intervention_name>
    <description>The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).</description>
    <arm_group_label>Afternoon First</arm_group_label>
    <arm_group_label>Morning First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI): 23 - 33 kg/m2&#xD;
&#xD;
          -  Participants diagnosed with Type 2 Diabetes (insulin independent) or Normal Glucose&#xD;
             Tolerant (2h oral glucose tolerance test within normal range).&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Ability to complete the exercise regiment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medications: Insulin&#xD;
&#xD;
          -  Current nicotine user (cigarettes, snus, nicotine gum) or past nicotine users less&#xD;
             than 6 months before inclusion in the study&#xD;
&#xD;
          -  Pre-existing cardiovascular condition (Angina pectoris, Cardiac arrhythmia, Cardiac&#xD;
             infarction, Coronary stent / angiography, Cerebrovascular insult, Hypertension [&gt; 160&#xD;
             mmHg systolic, or &gt; 95 mmHg diastolic])&#xD;
&#xD;
          -  Pre-existing blood-borne disease (HIV, Hepatitis C, MRSA)&#xD;
&#xD;
          -  Pre-existing systemic or localized rheumatic illness&#xD;
&#xD;
          -  Malignant Disease&#xD;
&#xD;
          -  Pre-existing psychiatric disorder&#xD;
&#xD;
          -  Another pre-existing systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet Wallberg-Henriksson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harriet Wallberg-Henriksson, MD PhD</last_name>
    <phone>+46-(0)70-629 64 70</phone>
    <email>harriet.wallberg@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17070</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HÃ¥kan Karlsson, PhD</last_name>
      <phone>+46-(0)73-712 14 37</phone>
      <email>hakan.karlsson.1@ki.se</email>
    </contact>
    <investigator>
      <last_name>Harriet Wallberg-Henriksson, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Harriet Wallberg</investigator_full_name>
    <investigator_title>Prof. MD PhD</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>High-intensity Intermittent Exercise</keyword>
  <keyword>Circadian Rhythm</keyword>
  <keyword>Glycemic Control</keyword>
  <keyword>Energy Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data underlying results reported in a publication will be shared after deidentification.</ipd_description>
    <ipd_time_frame>Data will be made available indefinetly after publication.</ipd_time_frame>
    <ipd_access_criteria>Data will be available for any purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

